A summary of mainstream reporting, plus the facts and perspectives it leaves out. A more honest account of each story.
Back to all stories

Boston Scientific cuts outlook, plans $500M cost reduction

Boston Scientific lowered its 2026 organic net sales growth outlook to 5-6% and announced a restructuring designed to cut about $500 million in annual costs.[1]

The company said the savings will come from supply-chain changes, production shifts and organizational restructuring, and that layoffs are expected though it did not specify job counts or affected sites.[1] CEO Mike Mahoney confirmed layoffs are expected but gave no specifics on numbers or locations.[1] The company employs about 59,000 people worldwide, including roughly 10,000 in Minnesota, where much of its cardiovascular work is based.[1] Its cardiovascular business accounted for 66% of 2025 net sales.[1]

Boston Scientific had earlier guided 10-11% organic net sales growth for 2026 before cutting the forecast to 5-6%.[1] Growth in its Minnesota-rooted Watchman heart implant has slowed sharply, and the company now expects 2026 global Watchman growth to be flat to low single digits as physicians change referral patterns.[1] That softer Watchman performance and the weaker revenue outlook prompted the restructuring plan.[1]

Investors and Minnesota officials will be watching for details on which sites and roles are affected as the company finalizes its cuts.

  1. Business Journal
Business & Economy Health
Show source details & analysis (1 source)

📌 Key Facts

  • Boston Scientific cut its 2026 organic net sales growth outlook from an initial 10–11% to 5–6%.
  • The company launched a restructuring plan intended to reduce annual expenses by about $500 million through supply-chain changes, production shifts and organizational restructuring.
  • Boston Scientific employs roughly 59,000 people worldwide, including about 10,000 in Minnesota, largely tied to its cardiovascular business that made up 66% of 2025 net sales.
  • Growth in its Minnesota-rooted Watchman heart implant has slowed sharply; 2026 global Watchman growth is now expected to be flat to low single digits as physicians change referral patterns.
  • CEO Mike Mahoney said layoffs are expected but did not specify how many jobs or which sites will be affected.

📰 Source Timeline (1)

Follow how coverage of this story developed over time

July 30, 2026